Smoking and rheumatoid arthritis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Rheumatoid arthritis is a chronic inflammatory disease caused by genetic and environmental factors. Smoking is the one of the most important external risk factors for development rheumatoid arthritis, severity, rapid disease progression and an unsatisfactory response to treatment. This findings determines the importance of studying smoking among patients with rheumatoid arthritis to identify barriers to smoking cessation and factors contributing to tobacco cessation, as well as to develop specific smoking cessation programs.

About the authors

Yuliya V. Khokhlova

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Author for correspondence.
Email: julia-khokhlova@mail.ru
ORCID iD: 0000-0002-3902-4873
SPIN-code: 2926-1461

postgraduate student

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint Petersburg

Olga M. Lesnyak

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Email: olga.m.lesnyak@yandex.ru
ORCID iD: 0000-0002-0143-0614
SPIN-code: 6432-4188

MD, Dr. Sci. (Med.), Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint Petersburg

Oksana V. Inamova

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Email: sekr@krb25.ru
ORCID iD: 0000-0001-9126-3639
SPIN-code: 8841-5496

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint Petersburg

Marianna S. Petrova

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Email: podagra@bk.ru
ORCID iD: 0000-0001-5261-6614

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint Petersburg

References

  1. Who.int [Internet]. WHO report on the global tobacco epidemic, 2021: addressing new and emerging products [updated 2021 Jul 16; cited 2023 Feb 11]. Available from: ttps://www.who.int/europe/ru/publications/i/item/9789240032095
  2. Andreeva EA, Pokhaznikova MA, Kuznetsova OYu. The prevalence of smoking among residents of two cities in the North-West region of Russia according to the RESPECT international study. Russian Journal of Preventive Medicine. 2020;23(1):92–99. EDN: NXIUYY doi: 10.17116/profmed20202301192
  3. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi: 10.1016/S0140-6736(17)31472-1
  4. Gwinnutt JM, Verstappen, SM, Humphreys JH. The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2020;34(2):101562. doi: 10.1016/j.berh.2020.101562
  5. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther. 2014;16(2):R61. doi: 10.1186/ar4498
  6. Hedström AK, Stawiarz L, Klareskog L, et al. Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study. Eur J Epidemiol. 2018;33(4):415–423. doi: 10.1007/s10654-018-0360-5
  7. Zhao SS, Holmes MV, Zheng J, et al. The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study. Rheumatology (Oxford). 2022;61(5):2167–2175. doi: 10.1093/rheumatology/keab654
  8. Seror R, Henry J, Gusto G, Aubin, et al. Passive smoking in childhood increases the risk of developing rheumatoid arthritis. Rheumato logy (Oxford). 2019;58(7):1154–1162. doi: 10.1093/rheumatology/key219
  9. Kim SK, Choe JY. Passive smoking is responsible for disease activity in female patients with rheumatoid arthritis. Arch Rheumatol. 2017;33(2):143–149. doi: 10.5606/ArchRheumatol.2018.6468
  10. Hedström AK, Klareskog L, Alfredsson L. Exposure to passive smoking and rheumatoid arthritis risk: results from the Swedish EIRA study. Ann Rheum Dis. 2018;77(7):970–972. doi: 10.1136/annrheumdis-2018-212973
  11. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(10):1223–1229. doi: 10.1093/rheumatology/kel094
  12. Reyes-Pérez IV, Sánchez-Hernández PE, Muñoz-Valle JF, et al. Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity. Clin Rheumatol. 2019;38(11):3061–3071. doi: 10.1007/s10067-019-04681-4
  13. Ishikawa Y, Ikari K, Hashimoto M, et al. Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Ann Rheum Dis. 2019;78(11):1480–1487. doi: 10.1136/annrheumdis-2019-215463
  14. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. doi: 10.1002/art.21575
  15. van Wesemael TJ, Ajeganova S, Humphreys J, et al. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res Ther. 2016;18(1):285. doi: 10.1186/s13075-016-1177-9
  16. Bracke K, Cataldo D, Maes T, et al. Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int Arch Allergy Immunol. 2005;138(2):169–179. doi: 10.1159/000088439
  17. Liu Y, Aryee MJ, Padyukov L, Fallin MD, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31(2):142–147. doi: 10.1038/nbt.2487
  18. Raitio A, Tuomas H, Kokkonen N, et al. Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers. Arch Dermatol Res. 2005;297(6):242–248. doi: 10.1007/s00403-005-0597-1
  19. Xue M, McKelvey K, Shen K, et al. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology (Oxford). 2014;53(12):2270–2279. doi: 10.1093/rheumatology/keu254
  20. Zhuo J, Xia Q, Sharma N, et al. The role of shared epitope in rheumatoid arthritis prognosis in relation to anti-citrullinated protein antibody positivity. Rheumatol Ther. 2022;9(2):637–647. doi: 10.1007/s40744-022-00427-y
  21. Hedström AK, Rönnelid J, Klareskog L, et al. Complex relationships of smoking, HLA-DRB1 genes, and serologic profiles in patients with early rheumatoid arthritis: update from a Swedish population-based case-control study. Arthritis Rheumatol. 2019;71(9):1504–1511. doi: 10.1002/art.40852
  22. Karami J, Aslani S, Jamshidi A, et al. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene. 2019;702:8–16. doi: 10.1016/j.gene.2019.03.033
  23. Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, et al. Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nat Genet. 2018;50(10):1366–1374. doi: 10.1038/s41588-018-0216-7
  24. Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009;41(12):1319–1324. doi: 10.1038/ng.480
  25. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis. 2013;72(5):652–658. doi: 10.1136/annrheumdis-2012-201484
  26. Kochi Y, Thabet MM, Suzuki A, et al. PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann Rheum Dis. 2011;70(3):512–515. doi: 10.1136/ard.2010.130526
  27. Massarenti L, Enevold C, Damgaard D, et al. PADI4 polymorphisms confer risk of anti-CCP-positive rheumatoid arthritis in synergy with HLA-DRB1*04 and smoking. Front Immunol. 2021;12:707690. doi: 10.3389/fimmu.2021.707690
  28. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related auto antibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756–1761. doi: 10.1002/art.34344
  29. Klareskog L, Gregersen PK, Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010;69(12):2062–2066. doi: 10.1136/ard.2010.142109
  30. Vesperini V, Lukas C, Fautrel B, et al. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. Arthritis Care Res. 2013;65(12):1899–1906. doi: 10.1002/acr.22057
  31. Roelsgaard IK, Ikdahl E, Rollefstad S, et al. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology (Oxford). 2020;59(8):1997–2004. doi: 10.1093/rheumatology/kez557
  32. Andersson MLE, Forslind K, Hafström I, et al. Patients with early rheumatoid arthritis in the 2000s have equal disability and pain despite less disease activity compared with the 1990s: Data from the BARFOT study over 8 years. J Rheumatol. 2017;44(6):723–731. doi: 10.3899/jrheum.161235
  33. Naranjo A, Toloza S, Guimaraes da Silveira I, et al. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol. 2010;28(6):820–827.
  34. Nyhäll-Wåhlin BM, Petersson IF, Nilsson JA, et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford). 2009;48(4):416–420. doi: 10.1093/rheumatology/kep004
  35. Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2776–2783. doi: 10.1002/art.22057
  36. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics – a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–1682. doi: 10.1093/rheumatology/keu165
  37. Wheeler AM, Baker JF, Poole JA, et al. Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum. 2022;57:152098. doi: 10.1016/j.semarthrit.2022.152098
  38. de Rooy DP, van Nies JA, Kapetanovic MC, et al. Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts. Ann Rheum Dis. 2014;73(7):1384–1387. doi: 10.1136/annrheumdis-2013-203940
  39. Nayebirad S, Javinani A, Javadi M, et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: A systematic review and meta-analysis. Mod Rheumatol. 2023;34(1):68–78. doi: 10.1093/mr/road013
  40. Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41(1):1–9. doi: 10.3109/03009742.2011.599073
  41. Levitsky A, Brismar K, Hafström I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD open. 2017;3(2):e000458. doi: 10.1136/rmdopen-2017-000458
  42. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69–74. doi: 10.1136/ard.2007.084715
  43. Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33(3):497–500.
  44. Metsios GS, Stavropoulos-Kalinoglou A, Nevill AM, et al. Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(1):70–73. doi: 10.1136/ard.2006.068403
  45. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711–715. doi: 10.1002/art.21671
  46. Liu X, Tedeschi SK, Barbhaiya M, et al. Impact and timing of smoking cessation on reducing risk of rheumatoid arthritis among women in the nurses’ health studies. Arthritis Care Res. 2019;71(7):914–924. doi: 10.1002/acr.23837
  47. Fisher MC, Hochberg MC, El-Taha M, et al. Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol. 2012;39(5):904–909. doi: 10.3899/jrheum.110852
  48. Andersson ML, Bergman S, Söderlin MK. The effect of stopping smoking on disease activity in rheumatoid arthritis (RA). Data from BARFOT, a multicenter study of early RA. Open Rheumatol J. 2012;6:303–309. doi: 10.2174/1874312901206010303
  49. Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PloS one. 2015;10(2):e0117952. doi: 10.1371/journal.pone.0117952
  50. Zhu D, Zhao G, Wang X. Association of smoking and smoking cessation with overall and cause-specific mortality. Am J Prev Med. 2021;60(4):504–512. doi: 10.1016/j.amepre.2020.11.003
  51. Naranjo A, Bilbao A, Erausquin C, et al. Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic. Rheumatol Int. 2014;34(1):93–99. doi: 10.1007/s00296-013-2851-8
  52. Aimer P, Treharne GJ, Stebbings S, et al. Efficacy of a rheumatoid arthritis-specific smoking cessation program: a randomized controlled pilot trial. Arthritis Care Res. 2017;69(1):28–37. doi: 10.1002/acr.22960
  53. Lopez-Olivo MA, Sharma G, Singh G, et al. A systematic review with meta-analysis of the effects of smoking cessation strategies in patients with rheumatoid arthritis. PloS one. 2022;17(12):e0279065. doi: 10.1371/journal.pone.0279065
  54. Schletzbaum M, Wang X, Greenlee R, et al. Predictors of smoking cessation in patients with rheumatoid arthritis in two cohorts: most predictive health care factors. Arthritis Care Res. 2021;73(5):633–639. doi: 10.1002/acr.24154
  55. Gath ME, Stamp LK, Aimer P, et al. Reconceptualizing motivation for smoking cessation among people with rheumatoid arthritis as incentives and facilitators. Musculoskeletal Care. 2018;16(1):139–146. doi: 10.1002/msc.1227
  56. Wattiaux A, Bettendorf B, Block L, et al. Patient perspectives on smoking cessation and interventions in rheumatology clinics. Arthritis Care Res. 2020;72(3):369–377. doi: 10.1002/acr.23858
  57. Laugesen M, Rasmussen M, Christensen R, et al. Smoking cessation rates among patients with rheumatoid arthritis and osteoarthritis following the ‘gold standard programme’ (GSP): a prospective analysis from the Danish smoking cessation database. Int J Environ Res Public Health. 2022;19(10):5815. doi: 10.3390/ijerph19105815
  58. Chow E, Williams M, Giri B, et al. Strategies to reduce the impact of smoking on rheumatoid arthritis outcomes: Clinical experience of a brief outpatient clinic screening questionnaire. Comment on “The impact of smoking on rheumatoid arthritis outcomes.” By Vittecoq et al. Joint Bone Spine. 2018;85:135–138. Joint Bone Spine. 2019;86(2):275. doi: 10.1016/j.jbspin.2018.09.012
  59. Karacabeyli D, Shojania K, Dehghan N, et al. Rheumatology health care providers’ views and practices on obesity and smoking cessation management in rheumatoid arthritis. Clin Rheumatol. 2021;40(7):2681–2688. doi: 10.1007/s10067-021-05607-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».